Compare Stocks: AYTU, APVO, and LPTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$1.60 -0.9%	$2.04	$1.37 ▼ $28.44	$2.92M	1.67	40,328 shs	8,563 shs
AYTU Aytu BioPharma	$1.96 -2.5%	$2.16	$1.80 ▼ $3.07	$21.84M	0.17	36,010 shs	6,942 shs
LPTX Leap Therapeutics		$2.05	$0.00 ▼ $0.00	$84.95M	-0.06	40.67 million shs	760.56 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	-0.93%	-7.51%	-11.60%	-63.39%	-94.34%
AYTU Aytu BioPharma	-2.49%	+0.51%	-7.98%	-9.26%	-16.95%
LPTX Leap Therapeutics	0.00%	0.00%	0.00%	0.00%	+204,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$1.60 -0.9%	$2.04	$1.37 ▼ $28.44	$2.92M	1.67	40,328 shs	8,563 shs
AYTU Aytu BioPharma	$1.96 -2.5%	$2.16	$1.80 ▼ $3.07	$21.84M	0.17	36,010 shs	6,942 shs
LPTX Leap Therapeutics		$2.05	$0.00 ▼ $0.00	$84.95M	-0.06	40.67 million shs	760.56 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	-0.93%	-7.51%	-11.60%	-63.39%	-94.34%
AYTU Aytu BioPharma	-2.49%	+0.51%	-7.98%	-9.26%	-16.95%
LPTX Leap Therapeutics	0.00%	0.00%	0.00%	0.00%	+204,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APVO Aptevo Therapeutics	1.00	Sell	N/A	N/A
AYTU Aytu BioPharma	2.00	Hold	$14.50	639.80% Upside
LPTX Leap Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest AYTU, APVO, and LPTX Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/14/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E) ➝ Sell (E+)
10/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D) ➝ Sell (D-)
10/5/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
9/25/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (E+) ➝ Sell (E)
9/22/2026	AYTU Aytu BioPharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Positive
9/22/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Sell (D)
9/10/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E) ➝ Sell (E+)
8/13/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (E+) ➝ Sell (E)
8/13/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
7/29/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	$17.42 per share	N/A
AYTU Aytu BioPharma	$57.57M	0.37	N/A	N/A	$3.29 per share	0.60
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.91 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APVO Aptevo Therapeutics	-$25.97M	-$51.83	N/A	N/A	N/A	N/A	-201.49%	-119.21%	11/5/2026 (Estimated)
AYTU Aytu BioPharma	-$14.25M	-$1.66	N/A	14.00	N/A	-24.76%	-56.54%	-13.14%	11/12/2026 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.22	N/A	N/A	N/A	N/A	-247.44%	-146.51%	N/A

Latest AYTU, APVO, and LPTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q1 2027	AYTU Aytu BioPharma	-$0.2567	N/A	N/A	N/A	$13.27 million	N/A
11/5/2026	N/A	APVO Aptevo Therapeutics	-$3.72	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	APVO Aptevo Therapeutics	-$6.0150	-$5.31	+$0.7050	-$5.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	N/A
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APVO Aptevo Therapeutics	N/A	2.08	2.08
AYTU Aytu BioPharma	0.26	1.13	1.00
LPTX Leap Therapeutics	N/A	1.34	1.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APVO Aptevo Therapeutics	8.06%
AYTU Aytu BioPharma	33.49%
LPTX Leap Therapeutics	30.46%

Insider Ownership

Company	Insider Ownership
APVO Aptevo Therapeutics	0.37%
AYTU Aytu BioPharma	4.90%
LPTX Leap Therapeutics	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APVO Aptevo Therapeutics	33	1.81 million	1.80 million	Not Optionable
AYTU Aytu BioPharma	83	10.87 million	10.34 million	Not Optionable
LPTX Leap Therapeutics	40	41.44 million	39.66 million	Optionable

AYTU, APVO, and LPTX Headlines

Recent News About These Companies

Leap Therapeutics stock steadies as investors await next clinical and earnings catalysts

September 20, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, APVO, and LPTX Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

$1.60 -0.02 (-0.93%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$1.59 -0.01 (-0.63%)

As of 06:24 AM Eastern

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Aytu BioPharma NASDAQ:AYTU

$1.96 -0.05 (-2.49%)

Closing price 10/21/2026 04:00 PM Eastern

Extended Trading

$1.98 +0.02 (+1.02%)

As of 10/21/2026 07:30 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Leap Therapeutics NASDAQ:LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AYTU, APVO, and LPTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AYTU, APVO, and LPTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AYTU, APVO, and LPTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, APVO, and LPTX Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

Aytu BioPharma NASDAQ:AYTU

Leap Therapeutics NASDAQ:LPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AYTU, APVO, and LPTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AYTU, APVO, and LPTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AYTU, APVO, and LPTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU, APVO, and LPTX Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

Aytu BioPharma NASDAQ:AYTU

Leap Therapeutics NASDAQ:LPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools